| Literature DB >> 29336364 |
Ze-Mou Yu1, Xiao-Tao Deng2, Ruo-Mei Qi3, Lu-Yan Xiao4, Chong-Qing Yang5, Tao Gong1.
Abstract
BACKGROUND: Chronic stress contributes to increased risks of atherosclerotic diseases including heart disease, stroke, and transient ischemic attack. However, its underline mechanisms are poorly understood. This study aimed to elucidate the mechanism via which chronic stress exerts its effect on atherosclerosis (AS).Entities:
Mesh:
Year: 2018 PMID: 29336364 PMCID: PMC5776846 DOI: 10.4103/0366-6999.222322
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Chronic stress procedures
| Methods | Time | |||||
|---|---|---|---|---|---|---|
| Monday | Tuesday | Wednesday | Thursday | Friday | Saturday | |
| Social stress | 4 h | 4 h | 4 h | 4 h | 4 h | 4 h |
| Physical stress | ||||||
| Overnight illumination | 12 h | – | – | – | – | – |
| White noise (80 db) | – | 2 h | – | – | – | – |
| Stroboscopic illumination | – | – | 2 h | – | – | – |
| Foot shock (1 mA) | – | – | – | 5 times | – | – |
–: Not available.
Primers for real time PCR
| Gene | Forward | Reverse | GenBank number |
|---|---|---|---|
| 5’-TCCTCTCCTACTTCGGGACC-3’ | 5’-AGTAAGAAAAACGCCTGTGTCC-3’ | XM_002723696.3 | |
| 5’-TTTTTCAACAGAGCGGTGCG-3’ | 5’-CGCTCTACCAGAGAACAGGC-3’ | XM_008261439.2 | |
| 5’-TTCCGTCACAGGGGCTATTT-3’ | 5’-GCATCTTGTGGGTCATCTGG-3’ | XM_002709395.3 | |
| 5’-GGTAGCGACAGAGTTCGAGT-3’ | 5’-TGAGAGGGAAGCAGAGTAACAG-3’ | XM_008273924.2 | |
| 5’-TGTTTCCGAGCGAGGGATTT-3’ | 5’-CGCAGGAAGGTTTTGGGGTA-3’ | XM_008249762.2 | |
| 5’-ATGCCTACCTCACGGGGTCT-3’ | 5’-AGGGTAGGGAACCAGCACCAT-3’ | NM_001082404.1 | |
| 5’-CTTTGCACGGGTTGTTGGTA-3’ | 5’-TGGTAGGGAGAGGGGCTTAT-3’ | NM_001081995.1 | |
| 5’-AGCTCTGTGTGGATCTGACAA-3’ | 5’-TGCCTGTAGTTTCAGTCCTTT-3’ | XM_002718039.3 | |
| 5’-ATGCGGATCAAACCTCACCA-3’ | 5’-TTTCGTTTTTGCCCCTTGCC-3’ | XM_017345155.1 | |
| 5’-TGGCGGTAGACTAGGGATGT-3’ | 5’-CCCATCGTTCCAGAAGGTGC-3’ | XM_002717799.3 | |
| 5’-TGGCTCTAACAGTCCGCCTAG-3’ | 5’-AGTGCGACGTGGACATCCG-3’ | NM_001101683.1 |
PCR: Polymerase chain reaction; BAX: Bcl-2 Associated X Protein; UBE2K: Ubiquitin-conjugating enzyme E2 K; CASP: Cysteinyl aspartate specific proteinase 3; ANG: Angiogenin; VEGF-A: Vascular endothelial growth factor-A; TSP-1: Thrombospondin-1.
Figure 1Assessments of chronic stress model. (a) Body weight. *P < 0.05 compared with Operation + HFD group. (b) Fur score. At week 8, *P < 0.001, ‡P < 0.001 compared with Control group; †P < 0.001 compared with Chronic Stress group; §P < 0.001 compared with Operation + HFD group. At week 12, *P < 0.001, ‡P < 0.001 compared with Control group; †P < 0.001 compared with Chronic Stress group; §P < 0.001 compared with Operation + HFD group. (c) Behavior assessments. At week 8, *P < 0.01, compared with Control group; †P < 0.001 compared with Control group, ‡P < 0.05 compared with Operation + HFD group; §P < 0.01 compared with Chronic Stress group. At week 12, *P < 0.01, †P < 0.001 compared with Control group, ‡P < 0.05 compared with Operation + HFD group; §P < 0.01 compared with Control group, ||P < 0.01 compared with Operation + HFD group; ¶P < 0.05, **P < 0.01 compared with Control group; ††P < 0.05 compared with Operation + HFD group. (d) Serum cortisol. At week 8, *P < 0.001, ††P < 0.001 compared with Control group, †P < 0.001, §P < 0.01 compared with Chronic Stress group, ||P < 0.01 compared with Operation + HFD group. At week 12, *P < 0.001, ‡P < 0.001 compared with Control group, †P < 0.001, §P < 0.001 compared with Chronic Stress group. (e) Adrenal weight/body weight. *P < 0.001, ††P < 0.001 compared with Control group, †P < 0.001, §P < 0.001 compared with Chronic Stress group. Data are shown as mean ± SE. and were analyzed by one-way analysis of variance. (Control group, n=9; Chronic Stress group, n=9; Operation+HFD group, n=14; Operation+HFD+Chronic Stress group, n=11).
Figure 2Assessments of chronic stress on lipids, inflammation, stenotic degree, intimal area and medial area. (a) Serum lipid profiles. At week 8, *P < 0.05, †P < 0.01 compared with Operation + HFD group. At week 12, *P < 0.05, †P < 0.01 compared with Operation + HFD group. (b) Serum hs-CRP. At week 8, *P < 0.01 compared with Control group, †P < 0.05 compared with Chronic Stress group, ‡P < 0.05 compared with Operation + HFD group. At week 12, *P < 0.001 compared with Control group, †P < 0.05 compared with Operation + HFD group. (c) Serum IL-6. At week 8, *P < 0.01, †P < 0.001, §P < 0.001 compared with Control group; ‡P < 0.001, ||P < 0.001 compared with Chronic Stress group; ¶P < 0.05 compared with Operation+HFD group. At week 12, *P < 0.05, †P < 0.001, §P < 0.001 compared with Control group; ‡P < 0.001, ||P < 0.001 compared with Chronic Stress group; ¶P < 0.01 compared with Operation+HFD group. (d) Gross examination, ×40. (e) H & E staining, original magnification ×40. (f) Comparison of stenotic degree. *P < 0.001, ‡P < 0.001 compared with Control group; †P < 0.001, §P < 0.001 compared with Chronic Stress group. (g) Comparison of intimal area. *P < 0.001, ‡P < 0.001 compared with Control group; †P < 0.001, §P < 0.001 compared with Chronic Stress group. (h) Comparison of medial area. *P < 0.01 compared with Control group, †P < 0.001 compared with Chronic Stress group, ‡P < 0.05 compared with Operation + HFD group. (i) Comparison of intima/media area ratio. *P < 0.001, ‡P < 0.001 compared with Control group; †P < 0.001, §P < 0.001 compared with Chronic Stress group. Bars represent SE. Data were analyzed by one-way analysis of variance. (Control group, n = 9; Chronic Stress group, n = 9; Operation + HFD group, n = 11; Operation + HFD + Chronic Stress group, n = 8).
Figure 3Assessments of chronic stress on plaque stability. (a) H & E staining for fibrous cap (red line), original magnification ×100. (b) Oil red O staining for lipid deposition, original magnification ×40. (c) Verhoeff–Van Gieson staining for elastic fiber (arrowhead, internal elastic lamina), original magnification ×100. (d) Immunostaining for macrophage marker CD68, original magnification ×100. Rectangle represents partial enlarged view, original magnification ×400. (e) Immunostaining for SMC (Dot, internal elastic lamina), original magnification ×100. (f) Immunostaining for new vessels (arrowhead), original magnification ×100. (g) Comparison of the maximum cap thickness, *P < 0.01. (h) Quantitative analyses of lipids, *P < 0.05. (i) Quantitative analyses of CD68, *P < 0.001. (j) Quantitative analyses of SMC, *P < 0.01. (k) Quantitative analyses of CD31, *P < 0.01. Bars represent SE. Data were analyzed by Student's t-test. (Operation + HFD group, n = 11; Operation + HFD + Chronic Stress group, n = 8).
Proteomics show the differential expression proteins in operation + HFD + chronic stress group when compared with operation + HFD group
| Accession | Description | Operation + HFD + chronic stress group/operation + HFD group |
|---|---|---|
| 291411929 | Predicted: ATP synthase subunit g, mitochondrial ( | 4128.734 |
| 655889416 | Predicted: Glycogen synthase kinase-3 alpha, partial ( | 1159.396 |
| 291395631 | Predicted: Histone H2B type 1 ( | 1054.544 |
| 291409112 | Predicted: Erlin-2 ( | 1054.078 |
| 655878391 | Predicted: 60S ribosomal protein L35 ( | 929.745 |
| 655879926 | Predicted: Histone-binding protein RBBP4 ( | 916.680 |
| 291391146 | Predicted: V-type proton ATPase subunit F ( | 829.562 |
| 655839882 | Predicted: Histone H2B type 1-B ( | 734.800 |
| 291390555 | Predicted: Heat shock factor-binding protein 1 ( | 608.791 |
| 655859728 | Predicted: Nebulette isoform X2 ( | 423.510 |
| 291404220 | Predicted: Eukaryotic translation initiation factor 4E-binding protein 2 ( | 403.829 |
| 291403459 | Predicted: Angiogenin ( | 348.576 |
| 655884244 | Predicted: Serum amyloid A-4 protein-like isoform X2 ( | 339.668 |
| 655861225 | Predicted: Receptor-type tyrosine-protein phosphatase C isoform X5 ( | 301.419 |
| 655830476 | Predicted: Serine/threonine-protein kinase 38-like isoform X4 ( | 296.165 |
| 655846531 | Predicted: Chromatin target of PRMT1 protein isoform X5 ( | 234.743 |
| 291397378 | Predicted: ATP-binding cassette subfamily F member 2 ( | 224.269 |
| 291413675 | Predicted: Fructosamine-3-kinase ( | 223.281 |
| 291396345 | Predicted: Ammonium transporter Rh type A ( | 169.990 |
| 655859026 | Predicted: Low quality protein: Selenide, water dikinase 1 ( | 78.302 |
| 655835923 | Predicted: Band 4.1-like protein 3 isoform X30 ( | 41.487 |
| 291415261 | Predicted: Pyridoxal kinase ( | 35.611 |
| 291396976 | Predicted: Syntaxin-7 ( | 31.425 |
| 126722836 | Complement component C8 gamma chain precursor ( | 29.150 |
| 655854442 | Predicted: Low quality protein: Profilin-2 ( | 27.553 |
| 291408940 | Predicted: Integral membrane protein 2B ( | 27.449 |
| 291396339 | Predicted: Methylmalonyl-CoA mutase, mitochondrial ( | 26.848 |
| 655853086 | Predicted: Schwannomin-interacting protein 1 isoform X4 ( | 25.985 |
| 291391482 | Predicted: Rab3 GTPase-activating protein catalytic subunit isoform X2 ( | 25.936 |
| 655903053 | Predicted: AH receptor-interacting protein ( | 25.411 |
| 291406912 | Predicted: Protein phosphatase 1F ( | 25.166 |
| 284005108 | Inactive rhomboid protein 1 ( | 24.739 |
| 291394851 | Predicted: 40S ribosomal protein S17 ( | 24.610 |
| 291385675 | Predicted: Ubiquitin-conjugating enzyme E2 K ( | 23.543 |
| 291388964 | Predicted: D-tyrosyl-tRNA (Tyr) deacylase 1 ( | 22.811 |
| 655871476 | Predicted: Membrane primary amine oxidase-like ( | 22.715 |
| 655835965 | Predicted: EMILIN-2 ( | 22.411 |
| 291398138 | Predicted: D-3-phosphoglycerate dehydrogenase ( | 22.262 |
| 655604166 | Predicted: Low quality protein: Cathepsin F ( | 21.431 |
| 655869908 | Predicted: Ankyrin repeat and FYVE domain-containing protein 1 ( | 21.316 |
| 291415948 | Predicted: Epiplakin ( | 21.074 |
| 291408920 | Predicted: Tubulointerstitial nephritis antigen-like ( | 18.701 |
| 291394602 | Predicted: Peptidyl-prolyl cis-trans isomerase FKBP14 ( | 16.238 |
| 655896783 | Predicted: Nuclear factor 1 X-type ( | 15.021 |
| 291398563 | Predicted: Transcription initiation factor IIB ( | 14.417 |
| 655838304 | Predicted: Endoplasmic reticulum aminopeptidase 1 isoform X2 ( | 14.254 |
| 291384137 | Predicted: Protein Hikeshi isoform X1 ( | 12.425 |
| 291398326 | Predicted: Glutathione S-transferase Yb-3 ( | 12.368 |
| 291392588 | Predicted: WW domain-binding protein 11 ( | 10.834 |
| 655715562 | Predicted: Receptor-type tyrosine-protein phosphatase alpha ( | 10.586 |
| 291398429 | Predicted: Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial ( | 9.410 |
| 655828146 | Predicted: SEC14 domain and spectrin repeat-containing protein 1 ( | 9.249 |
| 655875803 | Predicted: Low quality protein: Coiled-coil domain-containing protein 22 ( | 8.909 |
| 655898897 | Predicted: Kynurenine-oxoglutarate transaminase 1 isoform X5 ( | 8.695 |
| 655842122 | Predicted: Unconventional myosin-VI isoform X5 ( | 8.309 |
| 126723431 | Niemann-Pick C1 protein precursor ( | 6.097 |
| 291414997 | Predicted: Apoptosis regulator BAX isoform X2 ( | 6.008 |
| 655893680 | Predicted: Myelin basic protein ( | 2.772 |
| 655603017 | Predicted: Low quality protein: Transmembrane protease serine 13-like ( | 2.150 |
| 655845739 | Predicted: Myelin protein P0 ( | 2.052 |
| 655740408 | Predicted: Peripherin ( | 1.955 |
| 655877309 | Predicted: Myelin proteolipid protein isoform X1 ( | 1.674 |
| 655881879 | gdp | 1.605 |
| 291408454 | Predicted: 26S proteasome non-ATPase regulatory subunit 5 ( | 0.666 |
| 291403258 | Predicted: Thrombospondin-1 ( | 0.659 |
| 655851215 | Predicted: ER membrane protein complex subunit 1 isoform X5 ( | 0.654 |
| 126723743 | Sex hormone-binding globulin precursor ( | 0.647 |
| 291405213 | Predicted: Platelet glycoprotein Ib alpha chain ( | 0.643 |
| 655898355 | Predicted: Acidic leucine-rich nuclear phosphoprotein 32 family member A ( | 0.642 |
| 655831559 | Predicted: Alpha-2-macroglobulin-like isoform X1 ( | 0.636 |
| 655850855 | Predicted: PITH domain-containing protein 1 ( | 0.630 |
| 655897691 | Predicted: Low quality protein: Cytohesin-2 ( | 0.628 |
| 655835791 | Predicted: Ras-related protein Rab-31 ( | 0.626 |
| 284005433 | Serpin B10 ( | 0.622 |
| 126723213 | Tartrate-resistant acid phosphatase type 5 precursor ( | 0.621 |
| 291389840 | Predicted: Glycosyltransferase 8 domain-containing protein 2 isoform X2 ( | 0.618 |
| 655854509 | Predicted: Platelet glycoprotein V ( | 0.603 |
| 291411025 | Predicted: Syntaxin-4 ( | 0.603 |
| 126723155 | Decorin precursor ( | 0.595 |
| 655887741 | Predicted: Low quality protein: Syntaxin-binding protein 2 ( | 0.589 |
| 930841416 | Hemoglobin subunit beta-1/2 isoform 1 ( | 0.587 |
| 655900718 | Predicted: Fermitin family homolog 3 ( | 0.583 |
| 126723523 | Platelet microbicidal protein 1 precursor ( | 0.582 |
| 655841265 | Predicted: Trem-like transcript 1 protein ( | 0.573 |
| 148224174 | UDPglucuronosyltransferase 1-6 precursor ( | 0.551 |
| 126722759 | Hemoglobin subunit alpha-1/2 ( | 0.536 |
| 655846515 | Predicted: Protein S100-A1 ( | 0.516 |
| 291409859 | Predicted: Protein NipSnap homolog 1 ( | 0.512 |
| 291391299 | Predicted: cAMP-dependent protein kinase type II-beta regulatory subunit ( | 0.446 |
| 655882729 | Predicted: Cytochrome b-c1 complex subunit Rieske, mitochondrial ( | 0.431 |
| 655850387 | Predicted: Peptidyl-prolyl cis-trans isomerase E isoform X1 ( | 0.342 |
| 126723706 | Haptoglobin precursor ( | 0.309 |
O. cuniculus: Oryctolagus cuniculus; HFD: High fat diet.
Figure 4Chronic stress-induced plaque instability associate with increased apoptosis and angiogenin. (a) Enriched functions associated to the chronic stress to AS (the top 10 pathway). (b) BAX protein level. (c) UBE2K protein level. (d) BAX mRNA expression. *P < 0.01, †P < 0.01 compared with Control group; ‡P < 0.001 compared with Operation + HFD group. (e) UBE2K mRNA expression. *P < 0.05, †P < 0.01 compared with Control group; ‡P < 0.01 compared with Operation + HFD group. (f) The ratio of Bcl-2/BAX. *P < 0.001, †P < 0.001 compared with Control group; ‡P < 0.01 compared with Operation + HFD group. (g) FAS mRNA expression. *P < 0.05 compared with Control group; †P < 0.05 compared with Operation + HFD group. (h) Caspse3 mRNA expression. *P < 0.05 compared with Control group; †P < 0.05 compared with Operation + HFD group. (i) Caspase9 mRNA expression. *P < 0.001, †P < 0.001 compared with Control group; ‡P < 0.001 compared with Operation + HFD group. (j) P53 mRNA expression. *P < 0.05, †P < 0.001 compared with Control group; ‡P < 0.001 compared with Operation + HFD group. (k) Angiogenin protein level. (l) ANG mRNA expression. *P < 0.001, †P < 0.01 compared with Control group; ‡P < 0.001 compared with Operation + HFD group. (m) VEGF-A mRNA expression. *P < 0.001 compared with Control group; †P < 0.001 compared with Operation + HFD group. (n) TSP-1 mRNA expression. *P < 0.05 compared with Control group.